Case Study: Advanced Prostate Cancer Phase III Study
Source: QuintilesIMS
Two studies sought to evaluate the efficacy of the 15mg 4-month formulation or 22.5mg 6-month formulation in achieving castrate levels of testosterone (=1.735nmol/L) on Day 29 (i.e., 28 days after study drug injection).
The timelines for recruitment were short, but all of the patients for both studies were enrolled in half of the projected time. The Quintiles team worked extra hours to ensure that requests from the sponsor were met on time. Through close communication with the sponsor, and a robust presence and local expertise in South Africa, effort was made to ensure all of the customer's needs were met at all times.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more